Stock RGC REGENCELL BIOSCIENCE HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Regencell Bioscience Holdings Limited

Equities

RGC

KYG7487R1002

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
5.33 USD -17.87% Intraday chart for Regencell Bioscience Holdings Limited -0.37% -49.24%
2023 Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
2023 Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI

Valuation

Fiscal Period: June 2022 2023
Capitalization 1 450.3 299.8
Enterprise Value (EV) 1 434.7 288.7
P/E ratio -59.5 x -51.1 x
Yield - -
Capitalization / Revenue - -
EV / Revenue - -
EV / EBITDA -58,206,538 x -48,275,824 x
EV / FCF -161,653,517 x -126,861,822 x
FCF Yield -0% -0%
Price to Book 26.4 x 24.9 x
Nbr of stocks (in thousands) 13,013 13,013
Reference price 2 34.60 23.04
Announcement Date 10/31/22 10/27/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023
Net sales - - - - -
EBITDA - -0.8029 -1.355 -7.468 -5.981
EBIT 1 -0.391 -0.8124 -1.381 -7.618 -6.274
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -0.391 -0.8124 -1.347 -7.595 -6.062
Net income 1 -0.391 -0.8124 -1.347 -7.446 -5.871
Net margin - - - - -
EPS 2 -0.0391 -0.0812 -0.1347 -0.5815 -0.4512
Free Cash Flow - -0.5211 -0.2835 -2.689 -2.276
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/22/21 3/22/21 10/29/21 10/31/22 10/27/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023
Net Debt 1 1.84 2.68 3.62 - -
Net Cash position 1 - - - 15.6 11.1
Leverage (Debt/EBITDA) - -3.342 x -2.674 x - -
Free Cash Flow - -0.52 -0.28 -2.69 -2.28
ROE (net income / shareholders' equity) - 36.2% 40.5% -116% -41.7%
ROA (Net income/ Total Assets) - -134% -202% -51.9% -25.6%
Assets 1 - 0.6059 0.6662 14.36 22.94
Book Value Per Share 2 -0.1800 -0.2700 -0.4000 1.310 0.9200
Cash Flow per Share 2 0.0200 0.0400 0.0100 0.4900 0.1200
Capex - 0.12 - 0.78 0.03
Capex / Sales - - - - -
Announcement Date 3/22/21 3/22/21 10/29/21 10/31/22 10/27/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
REGENCELL BIOSCIENCE HOLDINGS LIMITED Stock Regencell Bioscience Holdings Limited
-49.24% 69.36M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RGC Stock
  4. Financials Regencell Bioscience Holdings Limited